As of November 10, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Nuo Therapeutics, Inc. The largest reported stake is Pittman Scott M.'s, at 11.6%. 3 filings are on record since January 26, 2026 (Schedule 13D/A, June 3, 2026).
Sell to companies like Nuo Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Pittman Scott M. · Sole voting: 5,627,500 · Shared voting: 0 · Sole dispositive: 5,627,500 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-06-03
- · Holder: Jacobs Paul Anthony · Percent: 6.6% · SCHEDULE 13G/A
- · Holder: Pittman Scott M. · Percent: 11.6% · SCHEDULE 13D/A
Nuo Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2026-01-26. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 11.6% | 5,627,500 | SCHEDULE 13D/A, 2026-06-03 | 2026-05-29 | |
| 6.6% | 3,183,500 | SCHEDULE 13G/A, 2026-02-12 | 2026-01-23 |
Holding shares or following this stake? See who's behind Nuo Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Nuo Therapeutics, Inc. and the records around it.
Nuo Therapeutics, Inc. elsewhere on the record
- Form D filing Aug 2025
Watch Nuo Therapeutics, Inc.
Get an email when Nuo Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nuo Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Nuo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nuo Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Pittman Scott M. | 5,627,500 | 0 | 5,627,500 | 0 | SCHEDULE 13D/A, 2026-06-03 |
The latest filing identifies Nuo Therapeutics, Inc. by CUSIP 67059V209 and gives its principal executive office as 8285 EL RIO, SUITE 190, HOUSTON, TX 77054 (SCHEDULE 13D/A, 2026-06-03).
Purpose of Transaction (Item 4)
Pittman Scott M.
Item 4 of this Schedule 13D is hereby amended as follows: On January 23, 2026, the closing (the "Initial Closing") occurred of a Loan and Security Agreement dated January 21, 2026 (the "Initial Loan Agreement") among the Company and certain lenders (including the Reporting Person). Upon the Initial Closing, the Reporting Person loaned $200,000 to the Company and, pursuant to the Initial Loan Agreement, committed to loaning $410,000 in a second funding, if requested by the Company, to be held on September 30, 2026 (a "Second Closing"). On May 29, 2026, the closing (the "Interim Closing") occurred of an Amended and Restated Loan and Security Agreement dated May 29, 2026 (the "Interim Loan Agreement") among the Company and certain lenders (including the Reporting Person). The Interim Loan Agreement amended and restated the Initial Loan Agreement. Upon the Interim Closing, the Reporting Person loaned $100,000 to the Company and, as amended pursuant to the Interim Loan Agreement, committed to loaning $100,000 in the Second Closing. At the Initial Closing, the Company issued a Secured Promissory Note (the "Initial Note") to each of the lenders (including the Reporting Person), at the Interim Closing, the Company issued a Secured Promissory Note (the "Interim Note") to each of the lenders (including the Reporting Person), and upon a Second Closing, if any, the Company will issue an additional Secured Promissory Note (a "Second Note") to each of the lenders (including the …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-03; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-26 | Pittman Scott M. | 11.6% | SCHEDULE 13D/A |
| 2026-02-12 | Jacobs Paul Anthony | 6.6% | SCHEDULE 13G/A |
| 2026-06-03 | Pittman Scott M. | 11.6% | SCHEDULE 13D/A |
Questions about who owns Nuo Therapeutics, Inc.
Who owns Nuo Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Nuo Therapeutics, Inc.: Pittman Scott M. (11.6%, Schedule 13D/A, filed 2026-06-03) and Jacobs Paul Anthony (6.6%, Schedule 13G/A, filed 2026-02-12).
Who are the largest shareholders of Nuo Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Nuo Therapeutics, Inc. on this page are Pittman Scott M. (11.6%) and Jacobs Paul Anthony (6.6%).
When did Pittman Scott M. buy into Nuo Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Pittman Scott M. on this page is the Schedule 13D/A, filed 2026-01-26, reporting 11.6%; its latest, Schedule 13D/A filed 2026-06-03, reports 11.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Nuo Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 4, 2025 | Form D, private offering | $791K sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Nuo Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.